The global non-cancerous blood disease market is anticipated to grow with a CAGR of 6.40% over the forecast period, i.e., 2022 - 2031. Factors such as the growing need for the early diagnosis of different types of non-cancerous blood diseases, followed by the surge in the burden for hemoglobinopathies across the globe, are anticipated to drive the growth of the market in the coming years. Additionally, the increasing prevalence of non-cancerous blood disorders globally, along with the growing research and development in this field, followed by the surge in expenditure on R&D activities are also expected to boost the market growth in the coming years. The market is estimated to garner a revenue of near to USD 105970 Million by the end of 2031, up from a revenue of more than USD 57220 Million in the year 2021.
The global non-cancerous blood disease market is segmented into numerous segments, which include segmentation by disorder type, treatment type, gender, end-user, and by region. By disorder type, the market is segmented into anemia, bleeding disorders, platelet disorders, white blood cell disorders, plasma cell disorders, rare hematological disorders, and spleen disorders. By the end of 2031, the bleeding disorders segment is projected to display the largest revenue of close to USD 29950 Million, up from a revenue of about USD 16570 Million in the year 2021.
On the basis of regional analysis, the global non-cancerous blood disease market is is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Europe region, out of the market in all the other regions, is anticipated to garner the largest revenue of over USD 39840 Million by the end of 2031. Additionally, in the year 2021, the market in the region generated a revenue of around USD 21340 Million.
Some of the prominent industry leaders in the global non-cancerous blood disease market that are included in our report are SANOFI, Novo Nordisk A/S, Novartis AG, Pfizer Inc., Amgen Inc., Alexion Pharmaceuticals, Inc., Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, CSL Behring, and others.
The global non-cancerous blood disease market is segmented into numerous segments, which include segmentation by disorder type, treatment type, gender, end-user, and by region. By disorder type, the market is segmented into anemia, bleeding disorders, platelet disorders, white blood cell disorders, plasma cell disorders, rare hematological disorders, and spleen disorders. By the end of 2031, the bleeding disorders segment is projected to display the largest revenue of close to USD 29950 Million, up from a revenue of about USD 16570 Million in the year 2021.
On the basis of regional analysis, the global non-cancerous blood disease market is is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Europe region, out of the market in all the other regions, is anticipated to garner the largest revenue of over USD 39840 Million by the end of 2031. Additionally, in the year 2021, the market in the region generated a revenue of around USD 21340 Million.
Some of the prominent industry leaders in the global non-cancerous blood disease market that are included in our report are SANOFI, Novo Nordisk A/S, Novartis AG, Pfizer Inc., Amgen Inc., Alexion Pharmaceuticals, Inc., Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, CSL Behring, and others.
Table of Contents
1. Market Definition and Research Methodology
3. Market Dynamics
14. Competitive Structure
15. Global Non-Cancerous Blood Disease Market
16. North America Non-Cancerous Blood Disease Market
17. Europe Non-Cancerous Blood Disease Market
18. Asia Pacific Non-Cancerous Blood Disease Market
19. Latin America Non-Cancerous Blood Disease Market
20. Middle East & Africa Non-Cancerous Blood Disease Market
Companies Mentioned
- SANOFI
- Novo Nordisk A/S
- Novartis AG
- Pfizer Inc.
- Amgen Inc.
- Alexion Pharmaceuticals Inc.
- Bayer AG
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Takeda Pharmaceutical Company Limited
- CSL Behring
